SELLAS Life Sciences (SLS) Share-based Compensation (2010 - 2026)
SELLAS Life Sciences' (SLS) quarterly Share-based Compensation came in at $798000.0 in Q1 2026, up 58.02% year-on-year from $505000.0 in Q1 2025, and up 78.52% on a QoQ basis from $447000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Share-based Compensation (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 16 years of Share-based Compensation data on file, last reported at $798000.0 in Q1 2026.
- On a quarterly basis, Share-based Compensation rose 58.02% year-over-year to $798000.0 in Q1 2026; TTM through Mar 2026 was $2.2 million, a 41.18% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 25.06% from the prior year.
- Share-based Compensation for Q1 2026 stood at $798000.0, up from $447000.0 in the prior quarter.
- Over the last five years, Share-based Compensation for SLS reached as high as $798000.0 in Q1 2026 and fell as low as -$1.2 million in Q4 2023.
- Historically, Share-based Compensation has averaged $342333.3 across 5 years, with a median of $476000.0 in 2024.
- Across the five-year window, Share-based Compensation jumped 594.59% in 2023 and tumbled 35.02% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $74000.0 in 2022, then tumbled by 1760.81% to -$1.2 million in 2023, then jumped by 130.35% to $373000.0 in 2024, then advanced by 19.84% to $447000.0 in 2025, then soared by 78.52% to $798000.0 in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $798000.0 in Q1 2026, $447000.0 in Q4 2025, and $503000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | 798,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 798,000.00 |
| Mar 31, 2026 | 798,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Sep 30, 2025 | 503,000.00 |
| Sep 30, 2025 | 503,000.00 |
| Jun 30, 2025 | 501,000.00 |
| Jun 30, 2025 | 501,000.00 |
| Mar 31, 2025 | 505,000.00 |
| Mar 31, 2025 | 505,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Jun 30, 2024 | 334,000.00 |
| Jun 30, 2024 | 334,000.00 |
| Mar 31, 2024 | 476,000.00 |
| Mar 31, 2024 | 476,000.00 |
| Dec 31, 2023 | -1.23 Mn |
| Dec 31, 2023 | -1.23 Mn |